Brinker Harding’s Stance on Big Pharma and His Financial Ties
Brinker Harding, a Republican candidate for Congress representing Nebraska’s 2nd District, is making waves with his pledge to challenge the pharmaceutical industry, despite holding substantial investments in it. Harding is currently serving as an Omaha city councilor and aims to win against his Democratic rival, Denise Powell, a small business owner.
In an August 4 social media video, Harding emphasized the need for affordable health care for Nebraskans, supporting a most-favored nation policy to reduce drug prices. This plan, initially proposed by President Donald Trump, seeks to align Medicaid drug payments with the lower prices found in other countries. The White House suggests such a move could save billions for the federal government, although critics argue it might not effectively diminish Big Pharma’s influence or significantly lower consumer costs.
Harding reiterated his support for this approach in a January op-ed, stating his desire to end taxpayer-funded bailouts that benefit big pharma and insurance companies.
Notably, financial disclosures reveal that Harding and his spouse have investments up to $125,000 in major pharmaceutical firms Pfizer and AbbVie. Both companies have faced legal challenges for price inflation and alleged profiteering, with Pfizer recently agreeing to a $50 million settlement for antitrust claims related to EpiPen pricing, as reported by Reuters. AbbVie has also been scrutinized for its pricing strategies, as discussed in an article on Forbes.
Despite entering a voluntary most-favored nation agreement with the Trump administration, both Pfizer and AbbVie raised drug prices in 2026, according to an NPR report.
Health care costs are a pivotal concern in this election cycle. Powell’s campaign emphasizes capping insulin prices at $35 monthly for all Americans, highlighting the ongoing debate over drug affordability.
Read more about this topic on American Journal News.
—
Read More Kitchen Table News
